Observational studyBMC psychiatry2018
Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study.
Observational study in BMC psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications.Frontiers in pharmacology · 2023Pooled it
- Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research.CNS drugs · 2022Pooled it
- Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial.Health technology assessment (Winchester, England) · 2025Trial
- Cortical morphometry might predict currently prescribed vs. discontinued medications in bipolar disorder, even after controlling for the cumulative dose effects: An ENIGMA mega-analysis.Molecular psychiatry · 2026Article
- An international, double-blind, randomized, placebo-controlled clinical trial of adjunctive trimetazidine to treat people with bipolar depression (the TIDE trial) protocol.BMC psychiatry · 2026Article
- Lithium Therapeutic Functions: An Update on Pharmacokinetics, Pathophysiological Mechanisms of Action, Toxicity, and Side Effects.Molecular neurobiology · 2026Review
- Article
- Lithium: Old Drug, New tricks?Current psychiatry reports · 2025Review
- The mood stabilizers lithium and valproate disrupt hepatic and intestinal farnesoid X receptor signalling and increase bile synthesis in the rat.Experimental physiology · 2025Article
- Kidney function decline improves after lithium discontinuation.Journal of internal medicine · 2025Article
- Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system.Therapeutic advances in psychopharmacology · 2025Article
- Review
- Lithium-discontinuation-induced treatment refractoriness revisited.International journal of bipolar disorders · 2024Review
- Ten-Year Trends in Lithium Prescribing in Alberta, Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Article
- Serious adverse drug events associated with psychotropic treatment of bipolar or schizoaffective disorder: a 17-year follow-up on the LiSIE retrospective cohort study.Frontiers in psychiatry · 2024Article
- Structure and Neuroprotector Properties of a Complex Compound of Lithium with Comenic Acid.International journal of molecular sciences · 2023Article
- Lithium prescription trends in psychiatric inpatient care 2014 to 2021: data from a Bavarian drug surveillance project.International journal of bipolar disorders · 2023Article
- Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study.International journal of bipolar disorders · 2023Article
- Lithium Treatment Induces Cardiac Dysfunction in Mice.International journal of molecular sciences · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLithium remains first choice as maintenance treatment for bipolar affective disorder. Yet, about half of all individuals may stop their treatment at some point, despite lithium's proven benefits concerning the prevention of severe affective episodes and suicide.
methodsRetrospective cohort study in the Swedish region of Norrbotten into the causes of lithium discontinuation. The study was set up to (1) test whether patients with bipolar affective disorder or schizoaffective disorder, treated with lithium maintenance therapy, were more likely to discontinue lithium because of adverse effects than lack of therapeutic effectiveness, (2) explore gender differences, (3) understand the role of diagnosis and (4) identify who, patient or doctor, took the initiative to stop lithium. Review of medical records for all episodes of lithium discontinuation that had occurred between 1997 and 2013 with the intent to stop lithium for good.
resultsOf 873 patients treated with lithium, 54% discontinued lithium, corresponding to 561 episodes of lithium discontinuation. In 62% of episodes, lithium was discontinued due to adverse effects, in 44% due to psychiatric reasons, and in 12% due to physical reasons interfering with lithium treatment. The five single most common adverse effects leading to lithium discontinuation were diarrhoea (13%), tremor (11%), polyuria/polydipsia/diabetes insipidus (9%), creatinine increase (9%) and weight gain (7%). Women were as likely as men to take the initiative to stop lithium, but twice as likely to consult a doctor before taking action (p < 0.01). Patients with type 1 BPAD or SZD were more likely to discontinue lithium than patients with type 2 or unspecified BPAD (p < 0.01). Patients with type 1 BPAD or SZD were more likely to refuse medication (p < 0.01). Conversely, patients with type 2 or unspecified BPAD were three times as likely to discontinue lithium for lack or perceived lack of effectiveness (p < 0.001).
conclusionsStopping lithium treatment is common and occurs mostly due to adverse effects. It is important to discuss potential adverse effects with patients before initiation and continuously during lithium treatment, to reduce the frequency of potentially unnecessary discontinuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.